Track topics on Twitter Track topics that are important to you
Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer SCLC remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis. Unlike nonsmall cell lung cancer NSCLC, in which major advances in treatment have been made following the approval of numerous targeted therapies, the field of SCLC has seen little advancement, and the standard of care SOC for several decades has been platinumetoposide chemotherapy. Limited tumor tissue for translational research, poor understanding of the mechanisms underlying disease biology, and therapeutic resistance are major factors impeding the discovery of effective drugs, including targeted therapies in SCLC, proving a major clinical need for patients.
To date, there have been three targeted therapies approved to treat SCLC, BristolMyers Squibb's Opdivo nivolumab, Roche's Tecentriq atezolizumab, and Merck Co.'s Keytruda pembrolizumab which were approved by the FDA in August 2018, March 2019 and June 2019, respectively. The recent approval of targeted and immunotherapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC. Following the approval of these new agents, relapsed/refractory patients are expected to have significantly improved therapeutic options. The increased prescription of branded therapies in treatmentnave and advanced patients will be the primary impetus driving the substantial growth in the SCLC market.
There are 165 pipeline programs in active development for SCLC. What proportion of these products are firstinclass?
How does firstinclass innovation vary by development stage and molecular target class?
Which molecular target classes are prominently represented in the firstinclass SCLC pipeline?
Which firstinclass targets have been identified as most promising for the treatment of SCLC?
How does the distribution of target classes differ in terms of development stage?
Across the SCLC landscape, there are 118 active companies. Which companies have formed partnerships?
Which companies have firstinclass assets in development with no prior deal involvement?
Reasons to buy
Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. Visualize the composition of the SCLC market in terms of dominant molecule types and molecular targets.
Analyze and compare the SCLC pipeline and stratify by stage of development, molecule type, and molecular target.
Assess the therapeutic potential of firstinclass targets. Using a proprietary matrix, firstinclass programs have been assessed and ranked according to their clinical potential. Promising firstinclass targets have been reviewed in greater detail.
Recognize commercial opportunities by identifying firstinclass pipeline programs for SCLC that have not yet been involved in licensing or codevelopment deals, and by analyzing company strategies in prior deals through case studies of key deals for firstinclass SCLC programs.
Original Article: Frontier Pharma Small Cell Lung Cancer: Diverse FirstinClass Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease [Published by Global Data] Prices from USD $6156NEXT ARTICLE
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...